News
-
-
-
-
PRESS RELEASE
Lumibird: FY revenue of EUR 225.6 million (+10.2% at constant scope and exchange rates)
LUMIBIRD Group achieves FY revenue of €225.6 million, up 10.2% at constant scope and exchange rates. Photonics division shows strong growth. Medical division sales stable reflecting resilient activity. 2025 EBITDA margin expected over 19% -
REGULATED PRESS RELEASE
Gimv verhoogt focus op strategische doelstellingen en discontinueert activiteiten voor nieuwe Life Sciences investeringen
Gimv verhoogt focus op strategische doelstellingen en stopt met Life Sciences investeringen. Raad van bestuur richt zich op Anchor, Consumer, Healthcare, Smart Industries en Sustainable Cities voor groei -
REGULATED PRESS RELEASE
Gimv increases focus on strategic objectives and discontinues activities for new Life Sciences investments
Gimv increases focus on strategic objectives by discontinuing new Life Sciences investments to concentrate on Consumer, Healthcare, Smart Industries, and Sustainable Cities sectors. Board focuses on digital transition growth opportunities -
-
PRESS RELEASE
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
Valbiotis launches a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges exclusively for its shareholders, strengthening the link with them and rewarding their commitment -
PRESS RELEASE
VALBIOTIS SA: Valbiotis lance un avantage commercial exclusif pour ses actionnaires : 20% de réduction sur ses gammes ValbiotisPRO® et ValbiotisPLUS®
Valbiotis lance un avantage commercial exclusif pour ses actionnaires : 20% de réduction sur ses gammes ValbiotisPRO® et ValbiotisPLUS®. Programme promotionnel renforce lien avec actionnaires -
